SCHEDULE 13D/A: Lipella CEO Secures Irrevocable Proxy Over Key Shares from Spartan Capital

Lipella Pharmaceuticals Inc. CEO, Dr. Jonathan Kaufman, has secured an irrevocable proxy from Spartan Capital Securities, LLC, granting him voting control over a significant block of shares issued for advisory and placement agent services.

Summary

• Lipella Pharmaceuticals Inc. (the Corporation) has entered into a consulting agreement and placement agent agreement with Spartan Capital Securities, LLC (Spartan).
• Under these agreements, Lipella is obligated to issue Spartan up to 1,050,000 shares of Series C Convertible Preferred Stock (Consultant Shares), convertible into up to 1,050,000 shares of Common Stock (Conversion Shares), for advisory and consultant services.
• Lipella also agreed to issue Spartan common stock purchase warrants (Warrant Shares) equal to 10% of the Series B non-voting convertible preferred stock sold in a private placement (the Offering) where Spartan serves as placement agent.
• As a material inducement for these agreements, Spartan has granted an Irrevocable Proxy and Power of Attorney to Dr. Jonathan Kaufman, Lipella's Chief Executive Officer, to represent and vote all Consultant Shares, Conversion Shares, and Warrant Shares (collectively, Proxied Shares) held by Spartan and its affiliates.
• This irrevocable proxy is coupled with an interest and is binding on Spartan's successors and assigns.
• Dr. Kaufman's beneficial ownership stands at 212,289 shares of Common Stock, representing 16.2% of the 1,208,919 shares outstanding as of September 30, 2024.
• The 212,289 shares include 112,352 shares purchased with personal funds and 99,937 shares from fully vested stock options.
• The Conversion Shares and Warrant Shares are not currently deemed beneficially owned by Dr. Kaufman because they are subject to a 4.99% beneficial ownership limitation, preventing their acquisition within 60 days.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the issuance of shares could imply future dilution, the primary focus of this filing is the establishment of an irrevocable proxy, which consolidates voting control with the CEO. This arrangement provides stability and aligns the voting power of these newly issued shares with existing management, which can be viewed favorably for corporate governance and strategic direction. The beneficial ownership limitation is a standard protective clause.

Positives

• The Irrevocable Proxy grants Dr. Jonathan Kaufman, the CEO, voting control over a significant block of shares issued to Spartan, potentially enhancing management stability and strategic alignment.
• The arrangement ensures that shares issued for services and placement agent activities are voted in alignment with the Corporation's Principal Stockholder's interests.
• The proxy is irrevocable and durable, surviving dissolution, bankruptcy, death, or incapacity of Spartan, providing long-term voting control.

Negatives

• The issuance of a substantial number of shares (up to 1,050,000 Series C Preferred and Warrant Shares) to Spartan could lead to future dilution of existing shareholders' equity upon conversion and exercise.
• The beneficial ownership limitation of 4.99% on the conversion of Preferred Stock and exercise of Warrants means that Spartan (and indirectly, Dr. Kaufman for beneficial ownership purposes) cannot immediately acquire all potential Common Stock, which could affect liquidity or full realization of the shares' value for Spartan.

Risks

• Future dilution risk from the conversion of Series C Preferred Stock and exercise of Warrants issued to Spartan.
• Restrictions on Spartan's ability to transfer Consultant Shares, Conversion Shares, and Warrant Shares without prior corporate consent and notice, and specific prohibitions on transfers to competitors or parties seeking control changes, which could limit Spartan's liquidity.
• The 4.99% beneficial ownership limitation on conversion and exercise of shares could delay or complicate Spartan's ability to fully realize the value of the shares received.

Future Outlook

The document indicates that the Corporation undertakes to include the maximum possible number of Conversion Shares and Warrant Shares in the initial and subsequent registration statements for reoffer and resale. It also states that transfer and notice restrictions will lift six months after any issuance if such shares are not then registered for resale.

Management Comments

• Dr. Jonathan Kaufman (President, CEO, Secretary, Treasurer, and Chairman of the Board of Directors of Lipella Pharmaceuticals Inc.) is the recipient of the irrevocable proxy, granting him voting power over the Proxied Shares.

Industry Context

This filing is a standard disclosure related to beneficial ownership and corporate control arrangements, common in smaller public companies or those undergoing financing activities. It reflects a mechanism to consolidate voting power with key management, which can be a strategy to maintain stability or facilitate future corporate actions, particularly when issuing shares for services or capital raises.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution from the conversion of preferred stock and exercise of warrants, though the irrevocable proxy ensures voting control of these shares remains with the CEO, potentially stabilizing governance.
• Spartan Capital Securities, LLC: Receives shares for services and placement agent activities but cedes voting control of these shares to the CEO and faces restrictions on their transfer, impacting their liquidity and control over the investment.

Next Steps

• The Corporation undertakes to include the maximum possible number of Conversion Shares and Warrant Shares in the initial and subsequent registration statements filed in connection with the Offering for reoffer and resale.
• Transfer and notice restrictions on Conversion Shares and Warrant Shares will terminate six months after any issuance if they are not then registered for resale.

Key Dates

Keywords

Irrevocable Proxy, Beneficial Ownership, SEC Filing, Schedule 13D/A, Preferred Stock, Common Stock, Warrants, Private Placement, Corporate Governance, Voting Rights, Lipella Pharmaceuticals, Spartan Capital Securities, Jonathan Kaufman